TNFRSF9 and neoplasm: The ability of 4-1BB/CD137 agonist monoclonal antibodies (mAb) to enhance T-cell mediated control of tumor growth has been known for almost 25 years, yet clinical application of this mechanism is hampered by the uncertain relationship between agonist dose, potency, and safety.